% | $
Quotes you view appear here for quick access.

Novavax, Inc. Message Board

  • xcohiba Mar 18, 2013 4:19 PM Flag

    Quote from Rotterdam conference................

    Novavax, Inc (NASDAQ:NVAX) announced results of preclinical findings on its respiratory syncytial virus (RSV) vaccine development program conducted on a cotton rat challenge model as well as humans. David C. Flyer, Ph.D., Director of Preclinical Development at Novavax, speaking at the XV International Symposium on Respiratory Viral Infections in Rotterdam, the Netherlands, said, “Both the human and cotton rat data suggest that our RSV vaccine candidate induced robust antibody responses with activity similar to palivizumab, which is a licensed anti-RSV monoclonal antibody indicated for the prevention of RSV disease in at-risk children and infants. These data provide further scientific evidence that our vaccine candidate may have the potential to safely protect infants in the first few months of life, where morbidity and mortality from RSV is greatest, as well as other affected populations including pediatric and elderly patients.”

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.505-0.155(-3.33%)3:35 PMEST